MedTrace Logo

Influenza Virus Challenge Study to Test Monoclonal Antibody TCN-032 as a Treatment for Influenza

NCT01719874 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2012-11-01

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of TCN-032 given to healthy adult volunteers that have been inoculated with the influenza A virus

Conditions

Interventions

BIOLOGICAL

TCN-032

BIOLOGICAL

Placebo (saline)

Sponsors & Collaborators

  • Theraclone Sciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Eleanor L Ramos, MD · Theraclone Sciences, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2012-12-31
Completion
2013-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01719874 on ClinicalTrials.gov